SGP
SpyGlass Pharma, Inc. Common Stock
1W: -2.0%
1M: -13.5%
YTD: -4.5%
$25.20
-0.02 (-0.08%)
After Hours: $24.95 (-0.25, -0.99%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$839.6M
52W Range20.16-32.44
Volume71,390
Avg Volume171,973
Beta0.00
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOPatrick Mooney
Employees1,489
SectorHealthcare
IndustryBiotechnology
IPO Date2008-01-08
Websitespyglasspharma.com
27061 Aliso Creek Road
Aliso Viejo, CA 92656
US
Aliso Viejo, CA 92656
US
1 949 535 0588
About SpyGlass Pharma, Inc. Common Stock
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA.
Latest News
SpyGlass Pharma, Inc. GAAP EPS of -$5.72
SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update
SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update
SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit
SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit
Recent Insider Trades
No insider trades found